Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

2014-08-27 03:40:51 | BioPortfolio


Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.

The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Central Serous Chorioretinopathy


Intravitreal injection of Bevacizumab


Asociacion para Evitar la Ceguera en Mexico
Mexico DF




Asociación para Evitar la Ceguera en México

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:40:51-0400

Clinical Trials [2349 Associated Clinical Trials listed on BioPortfolio]

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in cen...

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy

The purpose of this clinical study is to evaluate the efficacy and safety of selective retina therapy (SRT) using R:GEN, an approved laser device, in patients with central serous chorioret...

Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the...

PubMed Articles [6336 Associated PubMed Articles listed on BioPortfolio]

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy.

To clarify the distinct molecular pathogenesis of central serous chorioretinopathy (CSC) and pachychoroid neovasculopathy (PNV).

Clinical characteristics of pachydrusen in central serous chorioretinopathy.

To evaluate the clinical characteristics of pachydrusen in central serous chorioretinopathy (CSC) and investigate the relationship between choroidal circulation and pachydrusen.

Optical coherence tomography in diagnostics and treatment of central serous chorioretinopathy.

To identify the signs of leakage points in central serous chorioretinopathy (CSC) patients using optical coherence tomography (OCT) allowing focal laser photocoagulation (FLP) to be performed without ...

Morphological and Functional Changes Immediately After Half-Time Photodynamic Therapy in Patients With Central Serous Chorioretinopathy.

To evaluate early treatment outcomes of half-time photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC).

Choroidal Neovascularisation Complicating Chronic Central Serous Chorioretinopathy: The Discovery Rate on Multimodal Imaging.

To identify the image modality allowing identification of choroidal neovascularisation (CNV) complicating chronic central serous chorioretinopathy (CSCR), including fluorescein angiography (FA), indoc...

Medical and Biotech [MESH] Definitions

A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.

The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.

Macrophages found in the TISSUES, as opposed to those found in the blood (MONOCYTES) or serous cavities (SEROUS MEMBRANE).

Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.

One of two salivary glands in the neck, located in the space bound by the two bellies of the digastric muscle and the angle of the mandible. It discharges through the submandibular duct. The secretory units are predominantly serous although a few mucous alveoli, some with serous demilunes, occur. (Stedman, 25th ed)

More From BioPortfolio on "Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy"

Quick Search


Relevant Topic

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Searches Linking to this Trial